<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183752</url>
  </required_header>
  <id_info>
    <org_study_id>GRUPO RINT</org_study_id>
    <nct_id>NCT03183752</nct_id>
  </id_info>
  <brief_title>Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules</brief_title>
  <official_title>The Role of Insulin Resistance and the Effect of Metformin Use on Volume of Benign Thyroid Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitário Clementino Fraga Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitário Clementino Fraga Filho</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been shown that insulin might be involved in the pathogenesis of thyroid growth.

      Objective To evaluate the impact of IR and metformin use on the volume of benign thyroid
      nodules (TNs).

      Methods A randomized clinical trial to placebo (P) or MTF use. Previous fine needle
      aspiration confirming the diagnosis is necessary to inclusion. Patients will receive similar
      tablets of MTF and placebo and instruct to take 3 tablets/day of MTF (500mg/tablet). Thyroid
      volume, as TN volume, will be assess by ultrasound, both in the beginning, six months and one
      year after randomization, by the same researcher blinded regarding location group. Blood
      samples to measure: TSH, FT4, TPO-Ab, lipid profile, glucose and insulin were done after 8h
      fasting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been shown that insulin might be involved in the pathogenesis of thyroid growth.
      Previous studies suggest that metformin (MTF) therapy decreased thyroid volume and nodule
      size in subjects with insulin resistance (IR).

      Objectives To evaluate the impact of IR and metformin use on the volume of benign thyroid
      nodules (TNs).

      Methods A randomized clinical trial to placebo (P) or MTF use. Previous fine needle
      aspiration confirming the diagnosis is necessary to inclusion. Exclusion criteria were:
      nodules with a predominantly cystic pattern, pregnancy, diabetes, acromegaly, previous use of
      MTF, levothyroxine, corticoid or any weight loss medication in the past six months, hepatic
      or cardiac insufficiency, creatinine levels &gt; 1.4 mg/dL and MTF intolerance doses &gt;1.0
      gram/day. Patients will receive similar tablets of MTF and placebo and will be instructed to
      take 3 tablets/day of MTF (500mg/tablet). Thyroid volume, as TN volume, will be accessed by
      ultrasound, both in the beginning, six months and one year after randomization, by the same
      researcher blinded regarding location group. Blood samples to measure: TSH, FT4, TPO-Ab,
      lipid profile, glucose and insulin were done after 8h fasting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 13, 2015</start_date>
  <completion_date type="Anticipated">July 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized clinical trial with two groups: to use placebo or Metformine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The same researcher blinded regarding location group will access thyroid volume and thyroid nodule volume by ultrasound, in the beginning, six months and one year after randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>changes in nodule volume from baseline after metformin use</measure>
    <time_frame>one year</time_frame>
    <description>the impact of metformin on the volume of thyroid nodules</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in nodule volume from baseline and changes in homa-ir</measure>
    <time_frame>one year</time_frame>
    <description>the impact of insulin resistance in volume of thyroid nodules</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in TSH levels from baseline after metformin use</measure>
    <time_frame>one year</time_frame>
    <description>the impact of metformin use in TSH levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thyroid Nodule</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients randomized to Metformin group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients randomized to placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg metformin three times daily</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>MTF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mg placebo three times daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PLC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with benign nodules diagnosed by fine needle aspiration biopsy (FNAB)

        Exclusion Criteria:

          -  Nodules with a predominantly cystic pattern

          -  Eggshell calcification

          -  Coalescent thyroid nodules (not suitable for size analysis)

          -  Pregnancy

          -  Diabetes

          -  Acromegaly

          -  Previous use of MTF, levothyroxine, corticoid or any weight loss medication in the
             past six months

          -  Hepatic or cardiac insufficiency

          -  Creatinine levels &gt; 1.4 mg/dL

          -  MTF intolerance doses &lt; 1.0 gram/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UFRJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Teixeira, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UFRJ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Santos, MD</last_name>
    <phone>55 21 981669799</phone>
    <email>patriciaborges.endocrino@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Patricia Santos</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941913</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Santos</last_name>
      <phone>55 21 981669799</phone>
      <email>patriciaborges.endocrino@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitário Clementino Fraga Filho</investigator_affiliation>
    <investigator_full_name>Patricia Borges dos Santos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>thyroid</keyword>
  <keyword>insulin</keyword>
  <keyword>thyroid nodule</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>thyroid volume</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Thyroid Nodule</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

